Avelumab First-Line Maintenance Therapy: Managing Patients With Advanced Urothelial Carcinoma

被引：1

作者：

Lapuente, Maria ^{[1
]}

Conway, Dawn ^{[2
]}

Wood, Laura S. ^{[3
]}

Kehoe, Kiran ^{[4
]}

Bullock, Andrea Carroll ^{[5
]}

Devgan, Geeta ^{[6
]}

Burns, Kathleen D. ^{[7
]}

机构：

[1] Bartholomews Hosp, London, England

[2] Univ Chicago Med Illinois, Genitourinary Oncol, Chicago, IL USA

[3] Cleveland Clin Ohio, Taussig Canc Ctr, Cleveland, OH USA

[4] Mem Sloan Kettering Canc Ctr, New York, NY USA

[5] North Amer Med Commun EMD Serono, Rockland, MA, Brazil

[6] Pfizer, US Med Affairs, New York, NY USA

[7] City Hope Natl Med Ctr, Natl Canc Ctr, Duarte, CA USA

来源：

CLINICAL JOURNAL OF ONCOLOGY NURSING | 2023年 / 27卷 / 01期

关键词：

avelumab first-line maintenance; bladder cancer; immune-related adverse events; CHEMOTHERAPY; CANCER; CISPLATIN;

D O I：

10.1188/23.CJON.71-80

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BACKGROUND:The phase 3 of JAVELIN Bladder 100 trial demonstrated that avelumab first-line (1L) maintenance in addition to best supportive care significantly prolonged overall survival compared to best supportive care alone. It is now the standard of care for platinum-eligible patients with locally advanced or metastatic urothelial carcinoma that has not progressed with 1L platinum-containing chemotherapy.OBJECTIVES: This article provides considerations for oncology nurses to effectively implement avelumab 1L maintenance treatment in the clinical setting.METHODS: This article reviews clinical evidence and implications for oncology nurses caring for patients receiving avelumab 1L maintenance treatment.FINDINGS: Oncology nurses can provide compre-hensive care for patients with advanced urothelial carcinoma and ensure the safe and appropriate use of avelumab 1L maintenance treatment by educating patients and caregivers, ensuring correct adminis-tration, and promptly recognizing and managing immune-related adverse events.

引用

页码：71 / 80

页数：10

共 36 条

[1]

American Cancer Society, 2019, WHAT IS BLADD CANC

[2]

[Anonymous], Cancer Stat Facts: Bladder Cancer 2019

[3] Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events [J].

Brahmer, Julie R. ;

Abu-Sbeih, Hamzah ;

Ascierto, Paolo Antonio ;

Brufsky, Jill ;

Cappelli, Laura C. ;

Cortazar, Frank B. ;

Gerber, David E. ;

Hamad, Lamya ;

Hansen, Eric ;

Johnson, Douglas B. ;

Lacouture, Mario E. ;

Masters, Gregory A. ;

Naidoo, Jarushka ;

Nanni, Michele ;

Perales, Miguel-Angel ;

Puzanov, Igor ;

Santomasso, Bianca D. ;

Shanbhag, Satish P. ;

Sharma, Rajeev ;

Skondra, Dimitra ;

Sosman, Jeffrey A. ;

Turner, Michelle ;

Ernstoff, Marc S. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (06)

[4]

Cancer Therapy Advisor, 2020, CANC THERAPY ADVISOR

[5] Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986 [J].

De Santis, Maria ;

Bellmunt, Joaquim ;

Mead, Graham ;

Kerst, J. Martijn ;

Leahy, Michael ;

Maroto, Pablo ;

Gil, Thierry ;

Marreaud, Sandrine ;

Daugaard, Gedske ;

Skoneczna, Iwona ;

Collette, Sandra ;

Lorent, Julie ;

de Wit, Ronald ;

Sylvester, Richard .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (02) :191-199

[6] Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium:: Results of a randomized phase 2 trial [J].

Dogliotti, Luigi ;

Carteni, Giacomo ;

Siena, Salvatore ;

Bertetto, Oscar ;

Martoni, Andrea ;

Bono, Aldo ;

Amadori, Dino ;

Onat, Haluk ;

Marini, Luca .

EUROPEAN UROLOGY, 2007, 52 (01) :134-141

[7]

EMD Serono, 2021, HLTH CAN APPR BAV MA

[8]

EMD Serono, 2022, BAV FULL PRESCR INF

[9] Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline [J].

Gilligan, Timothy ;

Coyle, Nessa ;

Frankel, RichardM. ;

Berry, Donna L. ;

Bohlke, Kari ;

Epstein, Ronald M. ;

Finlay, Esme ;

Jackson, Vicki A. ;

Lathan, Christopher S. ;

Loprinzi, Charles L. ;

Nguyen, Lynne H. ;

Seigel, Carole ;

Baile, Walter F. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (31) :3618-+

[10] Oncology Nurse Participation in Survivorship Care [J].

Grant, Marcia ;

Economou, Denice ;

Ferrell, Betty Rolling .

CLINICAL JOURNAL OF ONCOLOGY NURSING, 2010, 14 (06) :709-715

← 1 2 3 4 →